Trevi Therapeutics, Inc. (TRVI)

SEC filing

Trevi Therapeutics, Inc.

TRVI · CIK 1563880

4 · Sep 17, 2026 · Director Heffernan Michael Thomas sold 39.47K shares at $15.09/share ($595.8K); exercised options for 78.95K shares

Director Heffernan Michael Thomas sold 39.47K shares at $15.09/share ($595.8K); exercised options for 78.95K shares

xslF345X06/ownership.xml

xslF345X06/ownership.xmlSEC.gov

Graphics and non-inline formats (not embedded below).